{"hands_on_practices": [{"introduction": "The TP53 gene is famously known as the \"guardian of the genome\" for its central role in preventing cancer formation. This exercise delves into the genetics behind its inactivation, a pivotal event in most human cancers. You will explore why the classical \"two-hit\" hypothesis for tumor suppressors doesn't always apply and how a single mutation can have a disproportionately powerful, dominant-negative effect through a fascinating application of probability. [@problem_id:4970427]", "problem": "A human epithelial cell carries a heterozygous missense mutation in Tumor Protein $53$ (TP53) that produces a stable p53 protein unable to bind Deoxyribonucleic Acid (DNA) and that co-assembles with wild-type p53 into tetramers. Tumor suppressors are defined as gene products whose physiological function constrains proliferation or survival; the Knudson two-hit hypothesis states that classical tumor suppressor inactivation generally requires two loss-of-function events, one in each allele. The Central Dogma of molecular biology posits that DNA is transcribed into Ribonucleic Acid (RNA), which is translated into protein, and transcription factors regulate target gene transcription by binding specific DNA motifs. Wild-type p53 functions as a tetrameric transcription factor (a complex of $4$ subunits), transactivating cell-cycle arrest and apoptosis genes (for example, Cyclin-dependent kinase inhibitor $1$A (CDKN1A, commonly called \"p21\"), Bcl-2-associated X protein (BAX), and $\\mathrm{p53}$ upregulated modulator of apoptosis (PUMA)) in response to genotoxic stress. In this cell, both alleles are expressed to similar levels, and tetramers assemble randomly from the available monomers. The mutant subunit exerts a dominant-negative effect: any tetramer containing at least $1$ mutant subunit is nonfunctional.\n\nBased on these principles, choose the single best statement that explains why this scenario differs from classical two-hit loss and predicts the qualitative and quantitative impact on transactivation of $\\mathrm{p53}$ target genes upon DNA damage.\n\nA. A single dominant-negative allele can markedly reduce p53 function without loss of heterozygosity because random tetramer assembly makes the probability of an all-wild-type tetramer $\\left(\\frac{1}{2}\\right)^4$, so transactivation of CDKN1A (\"p21\"), PUMA, and BAX is severely blunted after genotoxic stress.\n\nB. The phenotype is due to haploinsufficiency: with one mutant allele the dosage of functional p53 is halved but tetramers remain functional, so transactivation is approximately $\\frac{1}{2}$ of normal until a second hit occurs.\n\nC. Mouse Double Minute $2$ homolog (MDM2) selectively degrades mutant p53, preserving near-normal tetramer function after a single hit, so transactivation of cell-cycle arrest and apoptosis genes remains largely intact.\n\nD. Because p53 is a tumor suppressor, the Knudson two-hit hypothesis applies strictly; therefore, dominant-negative missense mutations require biallelic loss before transactivation is impaired.\n\nE. Random tetramer assembly yields most tetramers with at least $\\geq 3$ wild-type subunits, which are sufficient for function; therefore, transactivation remains high despite one dominant-negative allele.", "solution": "## Problem Validation\n\n### Step 1: Extract Givens\n1.  **Cell:** A human epithelial cell.\n2.  **Genotype:** Heterozygous missense mutation in the *TP53* gene.\n3.  **Allele Expression:** Both wild-type and mutant alleles are expressed to similar levels.\n4.  **Mutant Protein (p53-MT):**\n    *   It is a stable protein.\n    *   It is unable to bind Deoxyribonucleic Acid (DNA).\n    *   It co-assembles with wild-type p53 (p53-WT) into tetramers.\n5.  **Wild-Type Protein (p53-WT):**\n    *   Functions as a tetrameric transcription factor (a complex of $4$ subunits).\n    *   Transactivates target genes like *CDKN1A* (\"p21\"), *BAX*, and *PUMA* in response to genotoxic stress.\n6.  **Assembly Rule:** Tetramers assemble randomly from the available monomers.\n7.  **Functional Rule (Dominant-Negative Effect):** Any tetramer containing at least $1$ mutant subunit is nonfunctional.\n8.  **Definitions/Principles:**\n    *   **Tumor Suppressor:** A gene product whose function constrains proliferation or survival.\n    *   **Knudson Two-Hit Hypothesis:** Classical tumor suppressor inactivation requires two loss-of-function events.\n    *   **Central Dogma:** DNA is transcribed into RNA, which is translated into protein. Transcription factors regulate transcription by binding DNA.\n9.  **Question:** Explain why this scenario differs from classical two-hit loss and predict the qualitative and quantitative impact on the transactivation of p53 target genes.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is scientifically grounded, well-posed, and objective.\n*   **Scientific Soundness:** The scenario describes a well-established mechanism in cancer biology. The p53 protein is known to be a tetrameric transcription factor, and many pathogenic missense mutations in *TP53* exert a dominant-negative effect, precisely as described. The listed target genes are canonical p53 targets. The juxtaposition of this mechanism with the classical Knudson hypothesis is a standard topic in introductory molecular oncology.\n*   **Completeness and Consistency:** All information required for a probabilistic calculation is provided. The premises—that both alleles are expressed equally, assembly is random, and the mutant protein poisons the tetramer—are clear and consistent. The term \"stable\" for the mutant protein is consistent with its ability to co-assemble.\n*   **Well-Posedness:** The problem has a clear objective and a unique solution can be derived from the provided information. The terms are unambiguous.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. The solution process will now proceed.\n\n## Principle-Based Derivation\n\nThe problem describes a cell that is heterozygous for a missense mutation in the *TP53* gene. It is given that both the wild-type (WT) and mutant (MT) alleles are expressed to similar levels. This means that the pool of available p53 monomeric proteins consists of approximately $50\\%$ WT subunits and $50\\%$ MT subunits.\n\nLet $P(WT)$ be the probability of randomly selecting a WT monomer from the pool, and $P(MT)$ be the probability of selecting a MT monomer.\nBased on the problem statement, we have:\n$$P(WT) = 0.5 = \\frac{1}{2}$$\n$$P(MT) = 0.5 = \\frac{1}{2}$$\n\nThe p53 protein functions as a tetramer, a complex of $4$ subunits. The problem states that these subunits assemble randomly. A tetramer is functional only if it is composed exclusively of WT subunits. The mutant protein exerts a dominant-negative effect, meaning any tetramer containing one or more MT subunits is rendered nonfunctional.\n\nWe must calculate the probability of forming a functional tetramer. A functional tetramer must consist of $4$ WT subunits. The probability of this event, assuming independent random selection for each of the $4$ positions in the tetramer, is:\n$$P(\\text{Functional Tetramer}) = P(\\text{1st is WT AND 2nd is WT AND 3rd is WT AND 4th is WT})$$\n$$P(\\text{Functional Tetramer}) = P(WT) \\times P(WT) \\times P(WT) \\times P(WT) = (P(WT))^4$$\nSubstituting the value for $P(WT)$:\n$$P(\\text{Functional Tetramer}) = \\left(\\frac{1}{2}\\right)^4 = \\frac{1}{16} = 0.0625$$\n\nThis result indicates that only $6.25\\%$ of the p53 tetramers in this cell will be functional. The remaining $1 - \\frac{1}{16} = \\frac{15}{16} = 93.75\\%$ of tetramers will contain at least one mutant subunit and will be nonfunctional.\n\nThis differs starkly from the classical Knudson two-hit hypothesis for a recessive tumor suppressor. In that model, a \"first hit\" (e.g., a deletion or a null mutation) would result in a cell that produces protein from only one allele. If the remaining allele is wild-type, the cell would produce $50\\%$ of the normal amount of functional protein (a state of haploinsufficiency). In this dominant-negative scenario, a single missense mutation reduces the functional protein activity to just $6.25\\%$. This is a much more severe functional loss from a single allelic mutation.\n\nTherefore, this single heterozygous dominant-negative mutation has an effect that is quantitatively much greater than a simple loss of one allele and functionally approximates a biallelic (two-hit) loss of function. Consequently, the ability of p53 to transactivate its target genes (*CDKN1A*, *BAX*, *PUMA*) upon genotoxic stress will be severely impaired or \"blunted\".\n\n## Option-by-Option Analysis\n\n**A. A single dominant-negative allele can markedly reduce p53 function without loss of heterozygosity because random tetramer assembly makes the probability of an all-wild-type tetramer $\\left(\\frac{1}{2}\\right)^4$, so transactivation of CDKN1A (\"p21\"), PUMA, and BAX is severely blunted after genotoxic stress.**\n**Verdict: Correct.**\nThis statement accurately describes the dominant-negative mechanism as an exception to the classical two-hit model. It correctly performs the probabilistic calculation for functional tetramers, arriving at $(\\frac{1}{2})^4$. It correctly interprets this result as a \"marked reduction\" in function and correctly predicts the biological consequence: a \"severely blunted\" transactivation of target genes. This aligns perfectly with the derivation.\n\n**B. The phenotype is due to haploinsufficiency: with one mutant allele the dosage of functional p53 is halved but tetramers remain functional, so transactivation is approximately $\\frac{1}{2}$ of normal until a second hit occurs.**\n**Verdict: Incorrect.**\nThis statement describes haploinsufficiency, which applies to a recessive loss-of-function allele, not a dominant-negative one. The problem explicitly states a dominant-negative effect where the mutant protein poisons the complex. The functional level is not halved ($\\frac{1}{2}$), but reduced to $\\frac{1}{16}$, as calculated above.\n\n**C. Mouse Double Minute $2$ homolog (MDM2) selectively degrades mutant p53, preserving near-normal tetramer function after a single hit, so transactivation of cell-cycle arrest and apoptosis genes remains largely intact.**\n**Verdict: Incorrect.**\nThis option introduces a mechanism (selective degradation of mutant p53 by MDM2) that is contradicted by the problem statement. The givens specify that the mutant protein is \"stable\" and \"co-assembles with wild-type p53\". If it were selectively degraded, it could not exert its dominant-negative effect.\n\n**D. Because p53 is a tumor suppressor, the Knudson two-hit hypothesis applies strictly; therefore, dominant-negative missense mutations require biallelic loss before transactivation is impaired.**\n**Verdict: Incorrect.**\nThis statement is factually wrong. The Knudson two-hit hypothesis does not apply \"strictly\" to all situations. Dominant-negative mutations are a well-known major exception, where a single mutation in one allele can severely impair the function of a multimeric protein. The entire premise of the problem illustrates how a single hit impairs transactivation.\n\n**E. Random tetramer assembly yields most tetramers with at least $\\geq 3$ wild-type subunits, which are sufficient for function; therefore, transactivation remains high despite one dominant-negative allele.**\n**Verdict: Incorrect.**\nThis statement contains two falsehoods. First, a probabilistic calculation shows that the fraction of tetramers with $\\geq 3$ WT subunits is $P(4WT) + P(3WT, 1MT) = (\\frac{1}{2})^4 + \\binom{4}{3}(\\frac{1}{2})^3(\\frac{1}{2})^1 = \\frac{1}{16} + \\frac{4}{16} = \\frac{5}{16}$, which is not \"most tetramers\". Second, and more critically, it claims that tetramers with any mutant subunits (e.g., a $3$ WT, $1$ MT complex) are functional. This directly contradicts the problem's rule: \"any tetramer containing at least $1$ mutant subunit is nonfunctional\".", "answer": "$$\\boxed{A}$$", "id": "4970427"}, {"introduction": "A tumor is not a monolithic entity but an evolving ecosystem of distinct cell populations, or clones, each with its own set of mutations. Modern DNA sequencing allows us to analyze this clonal architecture, providing insights into a tumor's history and potential vulnerabilities. This practice challenges you to act as a cancer genomicist, interpreting sequencing data to distinguish between early \"trunk\" mutations that founded the tumor and later \"branch\" mutations that arose in subclones. [@problem_id:4970439]", "problem": "A resected carcinoma specimen is analyzed by bulk deep sequencing under conditions designed to minimize confounders: histopathology and copy-number profiling indicate a copy-number neutral, diploid tumor, and microdissection yields high tumor purity approximating $p \\approx 1$. Three heterozygous single-nucleotide variants (SNVs) are detected with variant allele fractions (VAFs) of $0.50$, $0.25$, and $0.05$. Variant allele fraction (VAF) is defined as the fraction of sequencing reads supporting the variant among all reads covering the locus.\n\nAssume all three SNVs are on autosomal loci without local copy-number change, and that read sampling is sufficiently deep that observed VAFs closely reflect underlying allele proportions. Using core definitions about diploidy and heterozygosity, and reasoning from the clonal composition of a tumor, infer which mutation is most consistent with a trunk event present in the founding clone and which are branch events present in subclones. Based on the principles of neoplastic evolution and the acquisition of cancer hallmarks, identify which of the three mutations is most likely to be a driver under these assumptions.\n\nChoose the single best option:\n\nA. Trunk: $0.50$; Branches: $0.25$, $0.05$; Likely driver: $0.50$.\n\nB. Trunk: $0.25$; Branches: $0.50$, $0.05$; Likely driver: $0.25$.\n\nC. Trunk: $0.50$; Branches: $0.25$, $0.05$; Likely driver: $0.05$.\n\nD. Trunk: $0.25$ and $0.05$ (co-trunk due to convergent evolution); Branch: $0.50$; Likely driver: $0.25$.", "solution": "The user wants me to solve a problem about cancer genomics. I will validate the problem statement, derive the solution from first principles, and evaluate each option.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n*   Specimen: A resected carcinoma.\n*   Tumor characteristics: Copy-number neutral, diploid.\n*   Sample purity: High, approximating $p \\approx 1$.\n*   Data: Three heterozygous single-nucleotide variants (SNVs).\n*   Observed Variant Allele Fractions (VAFs): $0.50$, $0.25$, and $0.05$.\n*   Definition: VAF is the fraction of sequencing reads supporting the variant among all reads covering the locus.\n*   Assumptions:\n    1.  SNVs are on autosomal loci.\n    2.  No local copy-number change.\n    3.  Observed VAFs closely reflect underlying allele proportions due to deep sequencing.\n*   Question:\n    1.  Infer which mutation is the trunk event and which are branch events.\n    2.  Identify which mutation is `most likely` to be a driver.\n\n**Step 2: Validate Using Extracted Givens**\n\n*   **Scientific Grounding (Critical):** The problem is firmly rooted in the principles of cancer genomics and clonal evolution. The concepts of diploidy, heterozygosity, variant allele fraction (VAF), tumor purity, copy-number neutrality, trunk/branch mutations, and driver/passenger mutations are all standard and well-defined in the field. The scenario is a well-established model for interpreting tumor sequencing data.\n*   **Well-Posed:** The problem is well-posed. The provided assumptions (diploid, copy-number neutral, purity $p \\approx 1$) are critical simplifications that remove major confounders and allow for a direct, quantitative interpretation of the VAFs. The data are sufficient to deduce the clonal architecture and make a reasoned inference about the nature of the mutations.\n*   **Objective (Critical):** The problem is stated using precise, objective terminology. The question asks for the `most likely` driver, which is an appropriate framing for a biological problem where certainty is often unattainable and inferences are made based on the weight of evidence.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is scientifically sound, well-posed, objective, and contains no internal contradictions or ambiguities. It is a valid problem that tests fundamental concepts in cancer biology. Therefore, a solution will be derived.\n\n### Solution Derivation\n\n**1. Fundamental Principles**\n\n*   **Diploidy and Heterozygosity:** The tumor is diploid, meaning each cell has two copies of each autosomal chromosome. A heterozygous single-nucleotide variant (SNV) is a mutation present on exactly one of these two copies at a specific locus.\n*   **Tumor Purity ($p$):** This is the fraction of cells in the sequenced sample that are tumor cells. We are given $p \\approx 1$, which means we can assume the sample consists entirely of tumor cells.\n*   **Cancer Cell Fraction (CCF or $C$):** This is the fraction of tumor cells that carry a specific mutation.\n*   **Variant Allele Fraction (VAF):** The VAF is the fraction of sequencing reads containing the variant allele. For a heterozygous SNV in a diploid, copy-number neutral region, the expected VAF is related to the CCF ($C$) and purity ($p$) by the formula:\n    $$ \\text{VAF} = \\frac{1}{2} \\times C \\times p $$\n    The factor of $\\frac{1}{2}$ arises because the mutation is heterozygous (on $1$ of $2$ alleles). The factor $C$ accounts for the fraction of tumor cells with the mutation. The factor $p$ accounts for the fraction of cells in the sample that are from the tumor.\n*   **Clonal Architecture:**\n    *   **Trunk Mutation:** An early mutation present in the founding tumor cell and, consequently, in all subsequent tumor cells. For a trunk mutation, the CCF is $C=1$.\n    *   **Branch Mutation:** A later mutation that arises in a subpopulation (a subclone) of the tumor. For a branch mutation, the CCF is $C < 1$.\n\n**2. Application to the Problem**\n\nGiven the assumption $p \\approx 1$, the formula simplifies to:\n$$ \\text{VAF} \\approx \\frac{1}{2} \\times C $$\nWe can rearrange this to estimate the Cancer Cell Fraction for each observed VAF:\n$$ C \\approx 2 \\times \\text{VAF} $$\n\nNow, let's calculate the CCF for each of the three SNVs:\n*   **SNV 1 (VAF = $0.50$):**\n    $$ C_1 \\approx 2 \\times 0.50 = 1.0 $$\n    A CCF of $1.0$ means this mutation is present in $100\\%$ of the tumor cells. By definition, this is a **trunk** mutation.\n\n*   **SNV 2 (VAF = $0.25$):**\n    $$ C_2 \\approx 2 \\times 0.25 = 0.50 $$\n    A CCF of $0.50$ means this mutation is present in $50\\%$ of the tumor cells. This is a **branch** mutation that defines a major subclone.\n\n*   **SNV 3 (VAF = $0.05$):**\n    $$ C_3 \\approx 2 \\times 0.05 = 0.10 $$\n    A CCF of $0.10$ means this mutation is present in $10\\%$ of the tumor cells. This is also a **branch** mutation, defining a smaller subclone.\n\n**3. Inference of the Likely Driver Mutation**\n\nThe problem asks to identify the `most likely` driver. A driver mutation is one that confers a selective growth advantage, promoting the expansion of the clone in which it resides.\n\n*   The mutation with VAF = $0.50$ is a **trunk** event. It is present in every single cell of the tumor ($C=1.0$). Its presence in the entire tumor mass implies it was acquired very early, in the cell that founded the tumor. For a tumor to form and grow, it must have acquired driver mutations. It is most parsimonious to assume that the mutation present in $100\\%$ of the cells is one of these foundational drivers.\n\n*   The mutation with VAF = $0.25$ is a **branch** event, defining a subclone that makes up $50\\%$ of the tumor. This subclone has clearly expanded successfully, suggesting this mutation may also be a driver that conferred a further selective advantage on top of the trunk mutation(s).\n\n*   The mutation with VAF = $0.05$ is a **branch** event in a small subclone ($10\\%$ of the tumor). It could be a recent driver, a weak driver, or simply a neutral passenger mutation that has not had time or selective pressure to expand.\n\nComparing the candidates, the trunk mutation (VAF=$0.50$) is the strongest candidate for being a driver. It is inextricably linked to the origin and existence of the entire tumor population. While the branch mutations *could* be drivers, the trunk mutation is the most fundamental to the neoplastic process described. Therefore, the mutation with VAF $0.50$ is the most likely driver.\n\n### Option-by-Option Analysis\n\n*   **A. Trunk: $0.50$; Branches: $0.25$, $0.05$; Likely driver: $0.50$.**\n    *   **Trunk/Branch classification:** The mutation with VAF=$0.50$ corresponds to a CCF of $1.0$, correctly identifying it as the trunk. The mutations with VAFs of $0.25$ and $0.05$ correspond to CCFs of $0.50$ and $0.10$ respectively, correctly identifying them as branches. This part is correct.\n    *   **Likely driver:** As derived above, the trunk mutation that defines the entire tumor is the most likely driver responsible for the initial clonal expansion. This part is correct.\n    *   **Verdict:** **Correct**.\n\n*   **B. Trunk: $0.25$; Branches: $0.50$, $0.05$; Likely driver: $0.25$.**\n    *   **Trunk/Branch classification:** This is incorrect. A VAF of $0.25$ in a diploid, pure tumor implies a CCF of $0.50$, which represents a subclone (a branch), not the trunk. The trunk mutation must have a CCF of $1.0$ (VAF of $0.50$).\n    *   **Verdict:** **Incorrect**.\n\n*   **C. Trunk: $0.50$; Branches: $0.25$, $0.05$; Likely driver: $0.05$.**\n    *   **Trunk/Branch classification:** This part is correct.\n    *   **Likely driver:** It is highly improbable that the mutation in the smallest subclone (VAF=$0.05$, CCF=$0.10$) is the most likely driver compared to the trunk mutation present in every cell. The extent of clonal expansion is a key indicator of selective advantage.\n    *   **Verdict:** **Incorrect**.\n\n*   **D. Trunk: $0.25$ and $0.05$ (co-trunk due to convergent evolution); Branch: $0.50$; Likely driver: $0.25$.**\n    *   **Trunk/Branch classification:** This is fundamentally incorrect. By definition, a trunk mutation is clonal (in all cells, CCF=$1.0$). Mutations with CCF < $1.0$ are subclonal (branch). The concept of a \"co-trunk\" for subclonal mutations is a misinterpretation of terminology, and classifying the VAF=$0.50$ mutation as a branch is incorrect.\n    *   **Verdict:** **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "4970439"}, {"introduction": "The ultimate goal of understanding cancer hallmarks is to translate that knowledge into clinical tools that save lives, such as early screening tests. This problem brings you to the front lines of diagnostic medicine, asking you to evaluate the real-world performance of a novel blood test for neoplasia. By applying Bayes' theorem, you will calculate the Positive Predictive Value ($PPV$) and uncover a crucial, often counterintuitive, statistical lesson about why a test with high accuracy can still yield a surprising number of false positives in a screening setting. [@problem_id:4970460]", "problem": "A biotechnology company develops a blood-based screening assay for early colorectal neoplasia that detects circulating tumor deoxyribonucleic acid (ctDNA) fragments associated with dysregulated proliferation, a hallmark of cancer. In an average-risk screening population, the assay’s performance has been validated against colonoscopic diagnosis and shows a sensitivity of $0.90$ and a specificity of $0.95$. The disease prevalence in this screened population is $0.02$. Using Bayes’ theorem and the standard definitions of sensitivity, specificity, and prevalence as foundational probability concepts, derive the Positive Predictive Value (PPV), defined as the probability of having disease given a positive test, from first principles. Then compute its numerical value for this assay in this population. Express your answer as a unitless probability in decimal form and round to four significant figures.", "solution": "The problem as stated is subjected to validation.\n\n### Step 1: Extract Givens\n- Sensitivity of the assay: $P(T^+ | D) = 0.90$\n- Specificity of the assay: $P(T^- | D^c) = 0.95$\n- Prevalence of the disease in the screened population: $P(D) = 0.02$\n- Definition of Positive Predictive Value (PPV): The probability of having the disease given a positive test, $P(D | T^+)$.\n- Task: Derive the PPV from first principles using Bayes' theorem and compute its numerical value, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, well-posed, and objective.\n- **Scientific Grounding**: The problem uses standard, well-defined concepts from epidemiology and biostatistics (sensitivity, specificity, prevalence, PPV, Bayes' theorem). The context of a ctDNA-based screening test for neoplasia is a current and valid topic in medical science. The provided numerical values are realistic for a screening assay.\n- **Well-Posedness**: The problem provides all necessary information to derive and compute the required quantity. The question is unambiguous and a unique, stable solution exists.\n- **Objectivity**: The problem is stated using precise, formal language without subjective or biased content.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. A solution will be provided.\n\n### Derivation and Solution\nLet $D$ be the event that an individual from the population has colorectal neoplasia, and let $D^c$ be the complementary event that the individual does not have the disease. Let $T^+$ be the event that the screening assay yields a positive result, and $T^-$ be the event that it yields a negative result.\n\nThe givens can be formally stated as probabilities:\nThe prevalence of the disease is $P(D) = 0.02$.\nThe probability of not having the disease is therefore $P(D^c) = 1 - P(D) = 1 - 0.02 = 0.98$.\nThe sensitivity is the probability of a positive test given the presence of disease, which is the true positive rate: $P(T^+ | D) = 0.90$.\nThe specificity is the probability of a negative test given the absence of disease: $P(T^- | D^c) = 0.95$.\nFrom the specificity, we can determine the false positive rate, which is the probability of a positive test given the absence of disease:\n$$P(T^+ | D^c) = 1 - P(T^- | D^c) = 1 - 0.95 = 0.05$$\n\nThe objective is to derive and compute the Positive Predictive Value (PPV), which is defined as the probability that an individual has the disease given that they received a positive test result, denoted as $P(D | T^+)$.\n\nWe begin from the definition of conditional probability:\n$$P(D | T^+) = \\frac{P(D \\cap T^+)}{P(T^+)}$$\n\nThe numerator, $P(D \\cap T^+)$, represents the joint probability of having the disease and testing positive. Using the definition of conditional probability, we can express this as:\n$$P(D \\cap T^+) = P(T^+ | D) P(D)$$\nThis is the probability of a true positive event occurring in the population.\n\nThe denominator, $P(T^+)$, is the total probability of receiving a positive test result. An individual can test positive in two mutually exclusive ways: they have the disease and test positive (a true positive), or they do not have the disease and test positive (a false positive). We use the Law of Total Probability to express $P(T^+)$:\n$$P(T^+) = P(T^+ \\cap D) + P(T^+ \\cap D^c)$$\nAgain using the definition of conditional probability for each term:\n$$P(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)$$\n\nSubstituting the expanded expressions for the numerator and denominator back into the formula for PPV gives us Bayes' theorem as applied to this problem:\n$$P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)}$$\nThis equation represents the PPV derived from first principles.\n\nNow, we substitute the given numerical values into this derived formula:\n- $P(D) = 0.02$\n- $P(D^c) = 0.98$\n- $P(T^+ | D) = 0.90$\n- $P(T^+ | D^c) = 0.05$\n\n$$P(D | T^+) = \\frac{(0.90)(0.02)}{(0.90)(0.02) + (0.05)(0.98)}$$\n\nWe compute the terms separately:\nThe probability of a true positive result in the population is the numerator:\n$$(0.90)(0.02) = 0.018$$\nThe probability of a false positive result in the population is the second term in the denominator's sum:\n$$(0.05)(0.98) = 0.049$$\n\nNow, we substitute these values back into the expression for PPV:\n$$P(D | T^+) = \\frac{0.018}{0.018 + 0.049} = \\frac{0.018}{0.067}$$\n\nFinally, we perform the division and round to four significant figures as requested:\n$$P(D | T^+) \\approx 0.2686567...$$\nRounding to four significant figures, we get $0.2687$.\n\nThis result signifies that for an individual in this average-risk population who receives a positive test result from this assay, the probability that they actually have colorectal neoplasia is approximately $26.87\\%$.", "answer": "$$\\boxed{0.2687}$$", "id": "4970460"}]}